<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00043420</url>
  </required_header>
  <id_info>
    <org_study_id>C014</org_study_id>
    <secondary_id>CO14, A8501014</secondary_id>
    <nct_id>NCT00043420</nct_id>
    <nct_alias>NCT00091208</nct_alias>
  </id_info>
  <brief_title>CPG 7909 in Patients With Cutaneous T-Cell Lymphoma</brief_title>
  <official_title>A Phase I/II Open Label, Multi-Center Study For The Evaluation Of Pf-3512676 (CPG 7909) In Patients With Stage Ib To Iva Cutaneous T-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of CPG 7909 Injection on Cutaneous T-cell lymphoma and the safety of CPG
      7909 Injection in patients with this cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Adverse events, vital signs, clinical and laboratory parameters, physical exams, and ECGs</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Evaluate tumor response as measured by the Composite Assessment of Index Lesion Disease Severity (CA). The primary endpoint will be the overall tumor response rate as assessed by the CA.</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy endpoints include disease response assessed by the PGA, duration of overall response, duration of CCR, duration of PR, time to response and time to progression of disease.</measure>
    <time_frame>indeterminate</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Lymphoma, T-Cell, Cutaneous</condition>
  <arm_group>
    <arm_group_label>Phase I: 0.08 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating dose groups: 0.08 mg/kg PF-3512676 Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: 0.16 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating dose groups: 0.16 mg/kg PF-3512676 Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: 0.24 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating dose groups: 0.24 mg/kg PF-3512676 Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: 0.28 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating dose groups: 0.28 mg/kg PF-3512676 Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: 0.32 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating dose groups: 0.32 mg/kg PF-3512676 Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: 0.36 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating dose groups: 0.36 mg/kg PF-3512676 Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase II: 10 mg flat dose (random assignment in Phase II)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-3512676</intervention_name>
    <description>Weekly subcutaneous injections of 0.08mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.</description>
    <arm_group_label>Phase I: 0.08 mg/kg</arm_group_label>
    <other_name>ProMune, CPG 7909</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-3512676</intervention_name>
    <description>Weekly subcutaneous injections of 0.16mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.</description>
    <arm_group_label>Phase I: 0.16 mg/kg</arm_group_label>
    <other_name>ProMune, CPG 7909</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-3512676</intervention_name>
    <description>Weekly subcutaneous injections of 0.24mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.</description>
    <arm_group_label>Phase I: 0.24 mg/kg</arm_group_label>
    <other_name>ProMune, CPG 7909</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-3512676</intervention_name>
    <description>Weekly subcutaneous injections of 0.28mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.</description>
    <arm_group_label>Phase I: 0.28 mg/kg</arm_group_label>
    <other_name>ProMune, CPG 7909</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-3512676</intervention_name>
    <description>Weekly subcutaneous injections of 0.32mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.</description>
    <arm_group_label>Phase I: 0.32 mg/kg</arm_group_label>
    <other_name>ProMune, CPG 7909</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-3512676</intervention_name>
    <description>Weekly subcutaneous injections of 0.36mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.</description>
    <arm_group_label>Phase I: 0.36 mg/kg</arm_group_label>
    <other_name>ProMune, CPG 7909</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-3512676</intervention_name>
    <description>Weekly subcutaneous injections of 10 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.</description>
    <arm_group_label>Phase II: 10 mg</arm_group_label>
    <other_name>ProMune, CPG 7909</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-3512676</intervention_name>
    <description>Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.</description>
    <arm_group_label>Phase II: 25 mg</arm_group_label>
    <other_name>ProMune, CPG 7909</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients 18 years or older with biopsy (histopathologically) confirmed cutaneous T-cell
        lymphoma (limited to mycosis fungoides (MF)) who have had prior therapy with at least one
        and no more than 3 systemic treatments.

        Exclusion Criteria:

        Patients with visceral involvement, serious infection or illness including human
        immunodeficiency virus infection, or a Karnofsky Performance Status (KPS) &lt; 60 will be
        excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=CO14&amp;StudyName=CPG%207909%20in%20Patients%20With%20Cutaneous%20T-Cell%20Lymphoma</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2002</study_first_submitted>
  <study_first_submitted_qc>August 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2002</study_first_posted>
  <last_update_submitted>February 11, 2009</last_update_submitted>
  <last_update_submitted_qc>February 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>immunotherapy, lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

